Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Optimal Paclitaxel Schedule Identified for Early-Stage Breast Cancer

June 4th 2013

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.

Dr. Hudis Highlights Two Abstracts From ASCO 2013

June 4th 2013

Clifford A. Hudis, MD, ASCO President-Elect, describes the focus on global medicine at the 2013 American Society of Clinical Oncology Annual Meeting.

More Evidence for 10-Years of Tamoxifen in ER+ Breast Cancer

June 3rd 2013

A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.

Richard Gray on a Longer Duration of Tamoxifen

June 2nd 2013

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Dr. O'Shaughnessy on Everolimus in Breast Cancer

June 1st 2013

Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.

Wicha Sees Potential for Significant Expansion of Anti-HER2 Therapy

May 31st 2013

Max S. Wicha, MD, is an internationally renowned research expert in the field of breast oncology. His lab was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

Dr. Piccart on the Success of Trastuzumab

May 30th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the success of trastuzumab for the treatment of breast cancer.

Neoadjuvant Regimen May Not Require Chemotherapy in Some HER2-Positive Breast Cancer Patients

May 29th 2013

Some HER2-positive breast cancer patients may be able to receive targeted neoadjuvant therapy with lapatinib and trastuzumab without chemotherapy.

Dr. Rugo on Chemotherapy for Metastatic Breast Cancer

May 28th 2013

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with metastatic breast cancer with chemotherapy.

Genetic Experts' Views Shift on Testing, Prophylactic Surgery

May 28th 2013

The decision about whether to get tested for a genetic mutation that may predispose a person to certain cancers is a difficult one for many patients to make. Even more difficult for mutation carriers is deciding whether to undergo a prophylactic surgical procedure.

Geriatric Assessments Should Guide Treatment Decisions in Older Patients

May 24th 2013

Breast cancer clinicians today are faced with an ever-expanding number of older patients, yet determining the most appropriate treatment for these individuals can be challenging.

Dr. Borgen on the Decision to be Tested for a BRCA Gene

May 23rd 2013

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses a patient's decision to be tested for a BRCA gene.

Chip Petricoin on the Discovery of New Biomarkers

May 20th 2013

Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

Resistance Poses Challenges in Chemotherapy Options

May 20th 2013

While chemotherapy might initially be effective in the treatment of patients with metastatic breast cancer, it is very common for patients to develop resistance to such agents.

LUX Program Examines Pan-HER Inhibitor Afatinib in Multiple Tumor Types

May 17th 2013

Researchers are attempting to determine if targeting more than one tyrosine kinase provide a greater benefit in several clinical trials involving the investigational drug afatinib.

A National Dialogue on Genetic Testing for Breast Cancer

May 16th 2013

A high-profile case of a medical decision being based primarily on the results of a genetic test has prompted a national discussion on the benefits and risks associated with acting on the results of such a test.

Sledge Expects "Big Data" to Generate Big Changes

May 15th 2013

The technological advances in analyzing the human genome have spawned a new era in breast cancer as well as other types of malignancies that will affect oncology practice and will necessitate dramatic changes in the clinical trials system.

Dr. Chagpar Discusses Sentinel Node Biopsying

May 15th 2013

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, gives an overview of the discussion surrounding sentinel node biopsying before and after neoadjuvant chemotherapy.

I-SPY Trials Seek Effective New Drug Combinations Using Adaptive Trial Design

May 14th 2013

The I-SPY trials are designed to test several different experimental therapies at once to determine which ones work best in which patients.

Anticipatory and Delayed Nausea Remain Concerns for Patients on Chemotherapy

May 13th 2013

Despite progress in treating chemotherapy-induced nausea and vomiting, especially in the acute phase up to 24 hours after treatment, the condition is still one of the side effects patients fear most.